Breast Cancer Preventive Effects of Anastrozole Persist Long After Stopping Treatment
SAN ANTONIO — Breast cancer incidence among postmenopausal women at high risk for developing the disease continued to be...
Search/Filter
Loading...
Partial Breast Irradiation May be as Effective as Whole Breast Irradiation in Preventing Recurrence in Patients with Early Breast Cancer
10-year follow-up data supports earlier findings on recurrence and survival SAN ANTONIO — A 10-year follow-up study of breast...
Neoadjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer with Lymph Node Involvement
SAN ANTONIO — The addition of the anti-PD-1 immunotherapeutic pembrolizumab (Keytruda) to neoadjuvant chemotherapy increased the rates of pathologic complete response (pCR)...
Combining Endocrine Therapy with a CDK4/6 Inhibitor Results In Similar Response Rates to Chemotherapy for High-Risk Luminal B Breast Cancer
SAN ANTONIO — Neoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response...
New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pretreated with T-DM1
SAN ANTONIO — The investigational HER2-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) demonstrated durable objective responses in patients with...
Updated APHINITY Trial Data Show Addition of Pertuzumab to Trastuzumab Plus Chemotherapy Continues to Yield Clinical Benefit in Patients With Operable HER2-positive Early Breast Cancer
SAN ANTONIO — Data from six-year analysis of the APHINITY trial showed that adding pertuzumab to the previous standard of trastuzumab...
Addition of S-1 to Post-operative Endocrine Therapy Improves Outcomes for Patients with Hormone Receptor-positive, HER2-negative Breast Cancer
SAN ANTONIO — A post-operative combination of S-1, an oral fluoropyrimidine-based drug, with endocrine therapy significantly increased invasive disease-free survival...
Tipifarnib Shows Promising Clinical Activity in Patients With HRAS-mutant Head and Neck Cancer
BOSTON – The investigational farnesyl transferase inhibitor tipifarnib yielded durable objective responses in patients with recurrent and metastatic head...
MRTX849 Shows Clinical Activity in Patients With KRAS G12C-mutant Solid Cancers
BOSTON The investigational KRAS G12C inhibitor MRTX849 yielded clinical responses in patients with non-small cell lung cancer (NSCLC) and...
Selumetinib Shows Clinical Benefit in Adult Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
BOSTON – The investigational MEK inhibitor selumetinib showed clinical responses in adult patients with neurofibromatosis type 1-associated plexiform neurofibromas,...